SV Atlas
← All founders
David Weinberg

David Weinberg

Developing the next generation of RNA medicines

Co-founderParcelBio logoParcelBio· Winter 2024San Francisco Bay Area
in LinkedIn
2023Co-founder· ParcelBio
Founder · since 2023
Company
ParcelBio
Role
Co-Founder and CEO
current
Stage
—
no public source
Raised
—
no public source
Based
San Francisco, California, United States
current
Founder / co-founder — the company's markEmployee / research role
Source: LinkedIn work history
Profile coverage5 of 7 · missing posts, contact
ParcelBio logo
ParcelBio

Elevated mRNA for transformative medicines.

Winter 2024

Experience

Career

  • ParcelBio logo

    ParcelBio

    Co-founder

    Co-Founder and CEO · San Francisco, California, United States · 2023 – Present

    2023
  • Orbital Therapeutics logo

    Orbital Therapeutics

    Vice President, RNA Platform · South San Francisco, California, United States · 2022 – 2023

    2022

  • Circ Bio (acquired by Orbital Therapeutics)

    Vice President, RNA Platform · South San Francisco, California, United States · 2021 – 2022

    2021
  • Freenome logo

    Freenome

    Senior Director, Molecular Research · South San Francisco, California, United States · 2020 – 2021

    2020
  • Freenome logo

    Freenome

    Director, Molecular Research · South San Francisco, California, United States · 2018 – 2020

    2018
  • Freenome logo

    Freenome

    R&D Team Lead · South San Francisco, California, United States · 2018

    2018
  • Freenome logo

    Freenome

    Principal Scientist · South San Francisco, California, United States · 2017 – 2018

    2017
  • UCSF logo

    UCSF

    Faculty Fellow and Principal Investigator · San Francisco, CA · 2013 – 2017

    2013
  • MIT logo

    MIT

    Graduate Student · Cambridge, MA · 2007 – 2013

    2007
  • Yale School of Medicine logo

    Yale School of Medicine

    Undergraduate Researcher · New Haven, CT · 2004 – 2007

    2004

Bio

David is the co-founder and CEO of ParcelBio. He was previously VP of RNA Platform at Orbital Therapeutics / Circ Bio, where he led the development of a circular RNA therapeutics platform. Before that, he was Sr. Director of Molecular Research at Freenome, where he built the multiomics diagnostics platform that enabled a blood test for the early detection of cancer​. David obtained his PhD from MIT, was a UCSF Faculty Fellow, and has been honored with Forbes ‘30 Under 30’ and an NIH DP5 Award.